The delay in regulatory approval for semaglutide in Canada led to a sharp revenue shortfall. With lower topline, operating leverage deteriorated, while operating expenses rose on a year-on-year basis.
The delay in regulatory approval for semaglutide in Canada led to a sharp revenue shortfall. With lower topline, operating leverage deteriorated, while operating expenses rose on a year-on-year basis.